Abstract Library

#4570 Diagnosis of carcinoid heart disease continues to be late delayed

Introduction: Carcinoid heart disease (CHD) is a serious complication of neuroendocrine tumours. It affects patients with carcinoid syndrome and results from fibrotic deposits on the heart valves. It significantly impacts patient prognosis.

Conference:

Presenting Author:

Authors: Sharma J, Shah T, Coldham C, Vickrage S, Rehman Z,

Keywords: carcinoid syndrome, neuroendocrine tumour, carcinoid heart disease, symptoms, presentation, echocardiogram, heart valves,

#4368 Surgical and multidisciplinary management of pancreatic neuroendocrine tumours with liver metastases: Insights from a high-volume centre

Introduction: Pancreatic neuroendocrine tumours (pNETs) are rare, with liver metastases posing significant prognostic challenges. MEN1-associated pNETs often present with multifocal and complex disease, requiring a tailored, multidisciplinary approach.

Conference:

Presenting Author: Yuntao B

Authors: Yuntao B, Chunhui Y, Lei L,

Keywords: Pancreatic Neuroendocrine Tumour, Liver Metastasis, MEN1, Multidisciplinary Team, Surgical Resection, Ki-67 Index, SSA, PRRT,

#4035 The safety and efficacy of surufatinib for the treatment of advanced neuroendocrine tumors: A prospective, multicenter, real-world study

Introduction: Surufatinib (a small-molecule inhibitor of VEGFR1-3, FGFR1, and CSF-1R) has exhibited encouraging antitumor activity for the treatment of advanced neuroendocrine tumors (including NET and NEC) in multiple registration studies.

Conference:

Presenting Author: Jiang L

Authors: Jiang L, Chuntao W, Beiyuan H, Tao C, Haitao G,

Keywords: neuroendocrine tumor, real-world study, surufatinib,

#3943 A case of conversion therapy for pancreatic neuroendocrine tumor with liver metastasis using Surufatinib combined with CAPTEM

Introduction: The preferred treatment for p-NETs is radical surgical resection. To increase the possibility of R0 resection, clinicians have been interested in conversion therapy which induces the tumor regression. However, no prospective studies have revealed which patients and p-NETs subcategory are suitable for conversion therapy and the best conversion therapy project.

Conference:

Presenting Author: Wang Z

Authors: Xie Z, Wang Z, Cao D, Ke N,

Keywords: p-NETs, conversion therapy, surufatinib, CAPTEM,

#3926 Epidemiology and outcomes of NET in a Portuguese cancer center

Introduction: NET make up 0.5% of all cancer diagnosis in Europe. They range from indolent to highly aggressive tumors and may cause a wide range of functional symptoms. Phase III trials are difficult because of poor accrual in a heterogenous group of rare tumors.

Conference:

Presenting Author: Magno S

Authors: Magno S, Esteves S, Leite V, Claro I, Pereira D,

Keywords: neuroendocrine, epidemiology, portugal, outcomes,